-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CAR-T cell therapy has shown significant efficacy in the treatment of hematological cancers, but it still faces multiple challenges in the treatment of solid tumors
Most of the proteins that drive tumorigenesis are intracellular proteins
In this study, the research team used multi-omics techniques to analyze 7608 polypeptides presented by MHC on the surface of neuroblastoma and found that a polypeptide produced by the PHOX2B gene is tumor-specific
However, since the PHOX2B polypeptide presented to the cell surface by MHC is relatively short, antibodies that can specifically bind to it but do not bind to normal cells are very rare
In animal models, this CAR-T cell therapy can significantly reduce the size of neuroblastoma transplanted into mice
Reference materials:
[1] Myrio Therapeutics data published in Nature: unlocking new targets for antibody-based therapies.
[2] CHOP researchers develop a new class of CAR-T cells that target previously untargetable cancer drivers.
(The original text has been deleted)